You are here

Mesodissection Device

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43GM100645-01
Agency Tracking Number: R43GM100645
Amount: $213,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIGMS
Solicitation Number: PA08-114
Timeline
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1290 W 2320 S, STE D
SALT LAKE CITY, UT 84119-1476
United States
DUNS: 967095378
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 NILS ADEY
 (801) 232-9200
 nils@avanscibio.com
Business Contact
 ROBERT PARRY
Phone: (435) 901-4516
Email: rparry@avanscibio.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Mesodissection Device Microscopic analysis of tissue mounted on glass slides is commonly used to study cancer, nonneoplastic entities such as heart disease and diabetes, and normal cell function. At a growing rate, researchers are utilizing various micro and macro tissue dissection techniques to recover specific areas of interest from a slide mounted tissue section for subsequent molecular testing including real time RTPCR, microarrays, sequencing, and mass spectrometry.The primary goal of the proposed Phase I project is to develop a manufacturing prototype of an inexpensive, manually controlled, dissection instrument for slide mounted tissue sections. This device will be based on an existing lab technology coinvented and exclusively licensed from the University of Utah's ARUP Laboratories. The subsequent commercial instrument would fill the need in the biological research market for a mesodissection (100,m resolution) instrument with the low cost, ease of use, and recovery efficiency of manual dissection techniques, but with far better precision. This device will include xy positioning, integrated optics, and multiple choices of specialized tissue removal and recovery tips. The manufacturing prototype will be tested for resolution, efficiency, and accuracy of tissue recovery. Resolution is defined as the difference in ,m between the circumference of the actual post dissection area and that of the originally indicated area for removal. Efficiency is defined as the percentage of tissue recovered from an indicated area measured by DNA quantification. Accuracy is defined as the percentage of desired DNA divided by the total DNA recovered and will be determined by DNA typing. Validation strategies are defined based on a model system of tissue type and slide type. By quantifying the resolution, efficiency and accuracy of DNA recovery in Phase I on prototype instruments we will demonstrate feasibility for Phase II development and commercialization. PUBLIC HEALTH RELEVANCE: Mesodissection Device The Mesodissection Device will provide a highly affordable system for dissection of tissue sections from glass slides. This device will provide 100m dissection resolution at an order of magnitude lower investment than that required forlaser capture microdissection, enabling much broader researcher access to the new technology. The technology will promote productivity and quality of results for researchers working in the fields of histopathology and cancer diagnostics, non cancer research including heart disease and diabetes, and areas outside of disease research including cell development and cellular function.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government